Abiopharma

🔍 McCoig Dain A (Executive)

Company: enCore Energy Corp. (EU)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 22,275 shares of Common Shares (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 25,695.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,424 shares of Common Shares at $1.87 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 20,271.00 | transaction_form_type: 4
• Sold 22,275 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 44,225.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one common share of enCore Energy Corp.
• F2: On October 8, 2025, the reporting person was granted 67,500 restricted stock units. The restricted stock units vested 33% on May 1, 2026 and will vest 33% on May 1, 2027 and 34% on May 1, 2028.